Technology Commercialization Office

Robert Lee, Melissa Bailey, and team of graduate nursing students named 2015 Innovators of the Year Written by The Ohio State University Office of Research As Ohio State continues to expand its role in the commercialization of research, it is important to create an environment that facilitates and rewards research creativity and entrepreneurship. To support and stimulate entrepreneurial activity among Ohio State researchers, three university-wide awards were presented on October

Straight from the labs of The Ohio State University Department of Electrical and Computer Engineering (ECE), a new motion-tracking device launching soon could make waves within the fields of medical sports therapy, sports training, military and even gaming. With the slogan “Own the 3rd Dimension!” SolitonReach introduces an inexpensive, wireless, long battery life and lightweight pathway into the 3D mobile device realm. The product debuts at the Disrupt TechCrunch San Francisco tech

The Ohio State University Ranked No. 29 on the Reuters Top 100: The World’s Most Innovative Universities Columbus, September 17, 2015 – The Ohio State University has ranked No. 29 in the inaugural Reuters Top 100: The World’s Most Innovative Universities, recognizing the university’s achievements in science and technology, and their impact on the global economy. The ranking uses proprietary data and analysis tools from the Intellectual Property & Science

Tuesday, June 23, 2015 Anne Co’s new, five-year $651,729 NSF CAREER Award for “Control of surface reactivity for catalyzing hydrocarbon formation from CO₂,” will allow her to expand her research on advanced  electrocatalytic materials for chemical conversion and energy storage. Co, assistant professor, chemistry and biochemistry; and her students, focus on fundamental studies of electrochemical reactions and electrocatalyst function. They investigate novel nanoporous electrode materials and single atomic layer model

Tuesday, June 2, 2015 | 10:00 AM – 11:00 AM |115 BRT Registration and more information is available at http://researchcalendar.osu.edu/index.php?eID=829   This presentation will provide details of the program, application process, award management process and summary of past funding rounds. An additional funding cycle with a proposal deadline in the fall of 2015 will be announced soon. Funding awards will be in the form of a grant. Up to $200,000

Sponsored by The Ohio State University Drug Development Institute and Charles River Laboratories Tuesday, April 28th 10:00am – 2:00pm Biomedical Research Tower, Room 115 460 West 12th Avenue Columbus, Ohio 43210 Ohio State’s Drug Development Institute and Charles River Laboratories are happy to announce a symposium detailing the drug discovery and development process as it is practiced in the pharmaceutical industry and in academia. The goal of this symposium is

The Commercialization Workshop Series walks participants through the commercialization process in eight workshops spanning January through August. Each interactive workshop will have subject matter experts discussing the topics while referencing a technology from Ohio State that has been commercialized. Come learn about commercialization and what resources are available to aid faculty and staff in that process. Introduction to Commercialization Workshop An Introduction to Commercialization is the first of eight workshops

Every day breakthrough innovations occur at The Ohio State University and sometimes these inventions need just a small amount of capital for further development. Seeing this need for proof of concept funding, the Technology Commercialization Office, Office of Research, and TechColumbus are implementing a new funding program known as the Accelerator Awards. The Accelerator Awards will provide a small amount of fast and flexible capital to Ohio State researchers to

Ohio-based Venture Therapeutics Named Industry Partner COLUMBUS, Ohio – The Ohio State University and the University of Michigan have signed an exclusive worldwide agreement with Ohio-based Venture Therapeutics, Inc., to form a new company to develop and commercialize a pharmaceutical technology targeted for the treatment of precancerous oral lesions. These lesions are currently managed by invasive surgery and approximately a third of these lesions will reoccur after surgery. Previously published

COLUMBUS, Ohio, and MIAMI, Florida–The Ohio State University, through the Ohio State Innovation Foundation, has signed an exclusive world-wide licensing agreement with MedVax Technologies, Inc., for the licensing of groundbreaking cancer peptide vaccine technologies. The anticancer vaccine technologies are designed for the treatment and prevention of cancers associated with the HER2 protein. These include breast, ovarian, lung, colon and pancreatic cancers, and gastrointestinal stromal tumors. The commitment by MedVax will allow